Chloroform provides clue to 150 year old medical puzzle

Mar 31, 2008

One of the earliest general anaesthetics to be used by the medical profession, chloroform, has shed light on a mystery that’s puzzled doctors for more than 150 years – how such anaesthetics actually work.

A discovery described as “true serendipity” made by Leeds University PhD student Dr Yahya Bahnasi, has provided a clue that may unravel the enigma of general anaesthesia – and offer the opportunity to design new generations of anaesthetics without harmful side effects.

“We take general anaesthesia for granted nowadays, but it’s still true to say that we don’t know exactly how it works on a molecular level,” says Dr Bahnasi, a qualified medical doctor on an Egyptian Ministry of Higher Education Scholarship at the University’s Faculty of Biological Sciences.

“However, I was examining the relationship between lipids and atherosclerosis [the furring up of arteries] and it just so happened that the lipids I was using were supplied already dissolved in chloroform. I noticed that the chloroform inhibited, or blocked, the calcium ion channel TRPC5 – it was quite a striking effect.”

Ion channels are pathways that allow electrically charged atoms to pass across cell membranes to carry out various functions such as pain transmission and the timing of the heart beat. TRPC5 calcium ion channels are found in many tissues around the body but are predominant in the brain.

“We know that this ion channel plays a signalling role in the central nervous system, which regulates the conscious and unconscious states, so I was left wondering whether inhibiting this calcium ion channel was one mechanism by which anaesthesia works,” says Dr Bahnasi.

Dr Bahnasi then carried out further experiments with several other modern anaesthetic compounds, both intravenous and inhaled, and found that the blocking effect on the TRPC5 ion channel was the same.

He says that the discovery opens up the opportunity to design and develop new generations of anaesthetics which directly target TRPC5, but with minimised side effects.

“Of course there are multi-molecular events that work together in anaesthesia, and inhibiting the TRPC5 ion channel may just be one of them. But it’s a great start in piecing together the underlying mechanisms and providing a novel molecular target for new drug design,” he says. “And it’s particularly fitting that this evidence was revealed by chloroform, the ‘grandfather’ of modern anaesthetics.”

Source: University of Leeds

Explore further: The impact of bacteria in our guts

add to favorites email to friend print save as pdf

Related Stories

Google buys travel guide app startup Jetpac

6 hours ago

Google confirmed Monday it has bought the startup behind a Jetpac mobile application that creates insightful travel guides by analyzing pictures from social networks such as Instagram.

Sharp Aquos Crystal phone: Where's the bezel?

6 hours ago

Just when you thought a fashionable gadget must be somewhat thin, Sharp is going to charm the smartphone fashion-conscious with a crazily thin phone, and it is arriving in the US quite soon. Gorgeous. Cool. ...

Recommended for you

The impact of bacteria in our guts

Aug 22, 2014

The word metabolism gets tossed around a lot, but it means much more than whether you can go back to the buffet for seconds without worrying about your waistline. In fact, metabolism is the set of biochemical ...

Stem cell therapies hold promise, but obstacles remain

Aug 22, 2014

(Medical Xpress)—In an article appearing online today in the journal Science, a group of researchers, including University of Rochester neurologist Steve Goldman, M.D., Ph.D., review the potential and ch ...

New hope in fight against muscular dystrophy

Aug 22, 2014

Research at Stockholm's KTH Royal Institute of Technology offers hope to those who suffer from Duchenne muscular dystrophy, an incurable, debilitating disease that cuts young lives short.

Biologists reprogram skin cells to mimic rare disease

Aug 21, 2014

Johns Hopkins stem cell biologists have found a way to reprogram a patient's skin cells into cells that mimic and display many biological features of a rare genetic disorder called familial dysautonomia. ...

User comments : 0